Rocket Pharmaceuticals, Inc. (RCKT) stock forecast and price target
Price $2.30 · data as of November 13, 2026
12-month price target
Average target$8.82
Upside / downside+283.4%
Analysts11
ConsensusBuy
Low $4.00Average $8.82High $15.00
Gold marker: average target · white marker: today’s price ($2.30)
Analyst ratings
Strong buy 1Buy 6Hold 6Sell 0Strong sell 1
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.12 | +94.2% | $920780 |
| Next fiscal year ends December 31, 2027 | $-1.57 | −1265.2% | $12M |
| Next quarter ends December 31, 2026 | $-0.42 | −11.0% | $763440 |
| Quarter after ends March 31, 2027 | $-0.41 | +1.6% | $3M |
Consensus of the analysts covering Rocket Pharmaceuticals, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.
Frequently asked questions
What is the Rocket Pharmaceuticals stock price target?
The average 12-month target from 11 analysts is $8.82, 283.4% above the current price of $2.30 Targets range from $4.00 to $15.00.
Is Rocket Pharmaceuticals a buy according to analysts?
The consensus rating is “Buy” (1 strong buy, 6 buy, 6 hold, 1 strong sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Rocket Pharmaceuticals expected to earn?
Analysts expect EPS of $-0.12 for the fiscal year ending December 31, 2026 and $-1.57 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.